Evidence map›Paper›PMID 38596222›Full record

ReviewFrontiers in endocrinology2024

Gut microbiota and therapy for obesity and type 2 diabetes.

Luyao Zhang, Pai Wang, Juan Huang, Yanpeng Xing, F Susan Wong, Jian Suo, Li Wen

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 36 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Semaglutide in Metabolic Medicine:Saudi medical journal · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Luyao Zhang *Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Pai Wang *Department of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Juan HuangSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Yanpeng XingDepartment of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
F Susan WongDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom.
Jian SuoDepartment of Gastrocolorectal Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, China.
Li WenSection of Endocrinology, Department of Internal Medicine, School of Medicine, Yale University, New Haven, CT, United States.
Yale University · USJilin University · CNCardiff University · GBFirst Hospital of Jilin University · CN

Funding

Antibody and gut bacteria in obesity and T2DR01DK126809 · NIDDK · YALE UNIVERSITY · PI WEN, LI · 2021 to 2024
$1.8M
Identifying immunoregulatory gut bacteria in type 1 diabetes and autoimmunityR01DK130318 · NIDDK · YALE UNIVERSITY · PI WEN, LI · 2022 to 2025
$1.6M
Investigating the early development of the immune system and islet autoimmunity later in lifeR01HD097808 · NICHD · YALE UNIVERSITY · PI WEN, LI · 2019 to 2021
$1.3M
Medical Research Council MR/K021141/1NICHD NIH HHS R01 HD097808NIDDK NIH HHS R01 DK126809NIDDK NIH HHS R01 DK130318
6 · The paper itself

Abstract

There has been a major increase in Type 2 diabetes and obesity in many countries, and this will lead to a global public health crisis, which not only impacts on the quality of life of individuals well but also places a substantial burden on healthcare systems and economies. Obesity is linked to not only to type 2 diabetes but also cardiovascular diseases, musculoskeletal disorders, and certain cancers, also resulting in increased medical costs and diminished quality of life. A number of studies have linked changes in gut in obesity development. Dysbiosis, a deleterious change in gut microbiota composition, leads to altered intestinal permeability, associated with obesity and Type 2 diabetes. Many factors affect the homeostasis of gut microbiota, including diet, genetics, circadian rhythms, medication, probiotics, and antibiotics. In addition, bariatric surgery induces changes in gut microbiota that contributes to the metabolic benefits observed post-surgery. Current obesity management strategies encompass dietary interventions, exercise, pharmacotherapy, and bariatric surgery, with emerging treatments including microbiota-altering approaches showing promising efficacy. While pharmacotherapy has demonstrated significant advancements in recent years, bariatric surgery remains one of the most effective treatments for sustainable weight loss. However, access to this is generally limited to those living with severe obesity. This underscores the need for non-surgical interventions, particularly for adolescents and mildly obese patients. In this comprehensive review, we assess longitudinal alterations in gut microbiota composition and functionality resulting from the two currently most effective anti-obesity treatments: pharmacotherapy and bariatric surgery. Additionally, we highlight the functions of gut microbiota, focusing on specific bacteria, their metabolites, and strategies for modulating gut microbiota to prevent and treat obesity. This review aims to provide insights into the evolving landscape of obesity management and the potential of microbiota-based approaches in addressing this pressing global health challenge.

Indexed as

Bariatric SurgeryDiabetes Mellitus, Type 2Gastrointestinal MicrobiomeAdolescentHumansObesityQuality of Lifebariatric surgerygut microbiotaobesitypharmacotherapytype 2 diabetes

Identifiers

PMID38596222
PMCPMC11002083
OpenAlexW4393198055

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.